Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (24081) 24081
Publication (3318) 3318
Book Review (480) 480
Newspaper Article (284) 284
Book Chapter (220) 220
Conference Proceeding (81) 81
Newsletter (80) 80
Magazine Article (42) 42
Book / eBook (24) 24
Dissertation (17) 17
Reference (10) 10
Trade Publication Article (6) 6
Transcript (4) 4
Web Resource (4) 4
Data Set (3) 3
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (13802) 13802
male (11220) 11220
dopamine (10824) 10824
neurosciences (10015) 10015
humans (9834) 9834
index medicus (9678) 9678
pharmacology & pharmacy (9171) 9171
rats (7917) 7917
psychiatry (5386) 5386
female (4546) 4546
dopamine - metabolism (3720) 3720
mice (3448) 3448
dose-response relationship, drug (3161) 3161
rats, sprague-dawley (3116) 3116
schizophrenia (3035) 3035
brain (2637) 2637
clinical neurology (2502) 2502
nucleus-accumbens (2473) 2473
adult (2423) 2423
article (2216) 2216
cocaine (2153) 2153
parkinson's disease (2134) 2134
serotonin (1992) 1992
motor activity - drug effects (1945) 1945
neurons (1912) 1912
rodents (1874) 1874
disease models, animal (1769) 1769
dopamine receptors (1764) 1764
middle aged (1721) 1721
ventral tegmental area (1721) 1721
behavior, animal - drug effects (1712) 1712
rats, wistar (1708) 1708
analysis (1690) 1690
receptors (1674) 1674
prefrontal cortex (1561) 1561
biomedicine (1532) 1532
rat (1520) 1520
parkinsons-disease (1508) 1508
time factors (1505) 1505
brain - metabolism (1498) 1498
brain - drug effects (1463) 1463
behavioral sciences (1444) 1444
neurology (1419) 1419
pharmacology/toxicology (1416) 1416
reward (1415) 1415
research (1390) 1390
dopamine antagonists - pharmacology (1373) 1373
antipsychotic agents - therapeutic use (1316) 1316
phenols (1315) 1315
pharmacology (1266) 1266
corpus striatum - metabolism (1259) 1259
schizophrenia - drug therapy (1223) 1223
glutamate (1199) 1199
antipsychotic agents - pharmacology (1197) 1197
amphetamine (1189) 1189
dopamine release (1181) 1181
striatum (1181) 1181
dopamine - physiology (1179) 1179
haloperidol (1168) 1168
corpus striatum - drug effects (1164) 1164
behavior (1145) 1145
nucleus accumbens (1143) 1143
double-blind (1114) 1114
addiction (1100) 1100
biochemistry & molecular biology (1094) 1094
in-vivo (1092) 1092
dopamine agonists - pharmacology (1076) 1076
drugs (1070) 1070
dopamine antagonists - therapeutic use (1066) 1066
physiological aspects (1042) 1042
basal ganglia (1031) 1031
mental disorders (1030) 1030
nervous system (1026) 1026
mice, inbred c57bl (1021) 1021
aged (1019) 1019
drug therapy (1016) 1016
receptors, dopamine d2 - metabolism (1001) 1001
reinforcement (1001) 1001
treatment outcome (998) 998
health aspects (975) 975
parkinson disease - drug therapy (971) 971
microdialysis (969) 969
drug interactions (968) 968
neurons - drug effects (937) 937
nucleus accumbens - drug effects (932) 932
care and treatment (922) 922
rat-brain (920) 920
analysis of variance (910) 910
medicine (907) 907
drug abuse (896) 896
dopamine agonists - therapeutic use (889) 889
psychopharmacology (867) 867
receptor (858) 858
receptors, dopamine - drug effects (853) 853
cocaine - pharmacology (851) 851
haloperidol - pharmacology (850) 850
neurons - metabolism (795) 795
serotonin - metabolism (791) 791
self administration (789) 789
neuroscience (780) 780
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (19) 19
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gerstein Science - Theses (1) 1
Online Resources - Online (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24203) 24203
French (94) 94
German (92) 92
Japanese (53) 53
Russian (45) 45
Spanish (43) 43
Polish (19) 19
Hungarian (17) 17
Portuguese (12) 12
Dutch (10) 10
Italian (10) 10
Chinese (7) 7
Danish (7) 7
Finnish (5) 5
Romanian (4) 4
Czech (3) 3
Turkish (3) 3
Ukrainian (3) 3
Bulgarian (2) 2
Hebrew (2) 2
Lithuanian (2) 2
Arabic (1) 1
Croatian (1) 1
Korean (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Dopamine D3 receptor antagonists as therapeutic agents
by Joyce, Jeffrey N and Millan, Mark J
Drug Discovery Today, ISSN 1359-6446, 07/2005, Volume 10, Issue 13, pp. 917 - 925
Dopamine D3 receptor antagonists could offer benefit in reducing cognitive and negative symptoms of schizophrenia without eliciting extrapyramidal symptoms;... 
Schizophrenia | positive symptoms | limbic system | extrapyramidal | cognition | cocaine | Humans | Dopamine Antagonists - therapeutic use | Technology, Pharmaceutical - methods | Tetrahydroisoquinolines - therapeutic use | Substance-Related Disorders - physiopathology | Technology, Pharmaceutical - trends | Animals | Substance-Related Disorders - prevention & control | Receptors, Dopamine D3 - physiology | Molecular Structure | Receptors, Dopamine D3 - antagonists & inhibitors | Dopamine Antagonists - chemistry | Nitriles - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The physiology, signaling, and pharmacology of dopamine receptors
by Beaulieu, Jean-Martin and Gainetdinov, Raul R
Pharmacological Reviews, ISSN 0031-6997, 03/2011, Volume 63, Issue 1, pp. 182 - 217
G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiological functions of the catecholaminergic neurotransmitter dopamine,... 
CAMP-REGULATED PHOSPHOPROTEIN | KNOCK-OUT MICE | HETEROTRIMERIC G-PROTEINS | TRANSLATIONAL PROFILING APPROACH | MESSENGER-RNA EXPRESSION | GLYCOGEN-SYNTHASE KINASE-3 | PHARMACOLOGY & PHARMACY | LONG-TERM POTENTIATION | MEDIUM SPINY NEURONS | METHAMPHETAMINE-USE DISORDER | PROTEIN-COUPLED-RECEPTOR | Dopamine Agonists - pharmacology | Humans | Dopamine Agonists - therapeutic use | Dopamine Antagonists - therapeutic use | Molecular Targeted Therapy | Receptors, Dopamine - chemistry | Gene Expression Regulation - drug effects | Animals | Signal Transduction - drug effects | Dopamine Antagonists - pharmacology | Ligands | Receptors, Dopamine - genetics | Receptors, Dopamine - physiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)
by Apovian, Caroline M and Aronne, Louis and Rubino, Domenica and Still, Christopher and Wyatt, Holly and Burns, Colleen and Kim, Dennis and Dunayevich, Eduardo and COR-II Study Grp and COR-II Study Group and for the COR-II Study Group
Obesity, ISSN 1930-7381, 05/2013, Volume 21, Issue 5, pp. 935 - 943
Objective: To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight‐related risk factors in overweight and obese... 
NUTRITION & DIETETICS | METAANALYSIS | OVERWEIGHT | ENDOCRINOLOGY & METABOLISM | ADULTS | HYPERTENSION | BLOOD-PRESSURE | LIFE | Naltrexone - therapeutic use | Dopamine Uptake Inhibitors - adverse effects | Dyslipidemias - complications | Obesity - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Dopamine Uptake Inhibitors - therapeutic use | Anti-Obesity Agents - adverse effects | Male | Weight Loss - drug effects | Anti-Obesity Agents - therapeutic use | Overweight | Naltrexone - pharmacology | Adult | Female | Drug Therapy, Combination | Bupropion - adverse effects | Bupropion - therapeutic use | Cardiovascular Diseases - etiology | Dopamine Uptake Inhibitors - pharmacology | Double-Blind Method | Obesity - complications | Risk Factors | Narcotic Antagonists - adverse effects | Feeding Behavior - drug effects | Nausea - etiology | Narcotic Antagonists - therapeutic use | Narcotic Antagonists - pharmacology | Obesity - prevention & control | Hypertension - complications | Quality of Life | Bupropion - pharmacology | Naltrexone - adverse effects | Anti-Obesity Agents - pharmacology | Delayed-Action Preparations | Hypertension | Studies | Obesity | Medical research | Nutrition research | Weight control | Behavior | Diabetes | Drug dosages | Food | Quality of life | Clinical Trials | Behavior, Pharmacotherapy, Devices, Surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Novel pharmacological targets for the treatment of Parkinson's disease
by Ferger, Borris and Novère, Nicolas Le and Davidai, Giora and Brotchie, Jonathan and Bezard, Erwan and Obeso, José A and Spampinato, Umberto and Collingridge, Graham L and Jenner, Peter and Schwarzschild, Michael A and Hirsch, Etienne and Hengerer, Bastian and Calon, Frédéric and Schapira, Anthony H. V
Nature Reviews Drug Discovery, ISSN 1474-1776, 10/2006, Volume 5, Issue 10, pp. 845 - 854
Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of Parkinson's... 
ADENOSINE A(2A) | INDUCED MOTOR COMPLICATIONS | MPTP-TREATED MONKEYS | LEVODOPA-INDUCED DYSKINESIAS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | NEUROTROPHIC FACTOR | A(2A) RECEPTOR ANTAGONIST | PHARMACOLOGY & PHARMACY | DOPA-INDUCED DYSKINESIAS | RANDOMIZED CONTROLLED-TRIAL | SEROTONIN 5-HT1A AGONIST | SUBUNIT MESSENGER-RNA | Monoamine Oxidase Inhibitors - therapeutic use | Excitatory Amino Acid Antagonists - therapeutic use | Antiparkinson Agents - pharmacology | Cholinergic Agents - therapeutic use | Humans | Dopamine Agonists - therapeutic use | Serotonin Antagonists - therapeutic use | Clinical Trials as Topic | Parkinson Disease - drug therapy | Adenosine A2 Receptor Antagonists | Antiparkinson Agents - therapeutic use | Serotonin Receptor Agonists - therapeutic use | Narcotic Antagonists - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Spinal segmental and supraspinal mechanisms underlying the pain-relieving effects of spinal cord stimulation: An experimental study in a rat model of neuropathy
by Barchini, J and Tchachaghian, S and Shamaa, F and Jabbur, S.J and Meyerson, B.A and Song, Z and Linderoth, B and Saadé, N.E
Neuroscience, ISSN 0306-4522, 2012, Volume 215, pp. 196 - 208
Highlights ► Chronic electrodes were implanted in the spinal cord and medulla of neuropathic rats. ► Spinal or dorsal column nuclei stimulation inhibits... 
Neurology | GABA | 5HT | neuropathic pain | spinal cord stimulation | noradrenaline | dopamine | Dopamine | Noradrenaline | Spinal cord stimulation | Neuropathic pain | AWAKE RATS | ANTINOCICEPTION | NEUROSCIENCES | DORSAL COLUMN STIMULATION | NEURONS | MONONEUROPATHIC RATS | RECEPTOR ACTIVATION | ANIMAL-MODEL | ROSTRAL VENTROMEDIAL MEDULLA | GAMMA-AMINOBUTYRIC-ACID | MODULATION | Pain Threshold - physiology | Baclofen - analogs & derivatives | Phentolamine - therapeutic use | Propranolol - therapeutic use | Electrodes - adverse effects | Adrenergic alpha-Antagonists - therapeutic use | GABA Antagonists - therapeutic use | Bicuculline - therapeutic use | Adrenergic beta-Antagonists - pharmacology | Time Factors | Pain Threshold - drug effects | Female | Neuralgia - physiopathology | Baclofen - therapeutic use | Disease Models, Animal | Sulpiride - therapeutic use | Ketanserin - therapeutic use | Rats | Serotonin Antagonists - therapeutic use | Methysergide - therapeutic use | Rats, Sprague-Dawley | Hyperalgesia - physiopathology | Pain Measurement - methods | Animals | Hyperalgesia - therapy | Analysis of Variance | Dopamine Antagonists - pharmacology | Spinal Cord - physiology | Neuralgia - therapy | Transcutaneous Electric Nerve Stimulation - methods | Physiological aspects | Neurosciences
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - An update
by Fredholm, Bertil B and IJzerman, Adriaan P and Jacobson, Kenneth A and Linden, Joel and Müller, Christa E
Pharmacological Reviews, ISSN 0031-6997, 03/2011, Volume 63, Issue 1, pp. 1 - 34
In the 10 years since our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors,... 
A RECEPTOR | PROTEIN-COUPLED RECEPTOR | XANTHINE DERIVATIVES | HIGHER-ORDER OLIGOMERS | DOPAMINE D-1 RECEPTORS | BIOLOGICAL EVALUATION | PHARMACOLOGY & PHARMACY | A(2A) RECEPTOR | ALLOSTERIC MODULATION | MICE LACKING | Receptors, Purinergic P1 - genetics | Animals, Genetically Modified | Humans | Purinergic P1 Receptor Agonists - pharmacology | Purinergic P1 Receptor Antagonists - therapeutic use | Terminology as Topic | Receptors, Purinergic P1 - physiology | Molecular Targeted Therapy | Purinergic P1 Receptor Agonists - therapeutic use | Purinergic P1 Receptor Antagonists - pharmacology | Receptors, Purinergic P1 - chemistry | Receptors, Purinergic P1 - classification | Animals | International Agencies | IUPHAR Nomenclature Report
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents:  Potential Therapeutics for Neurological and Psychiatric Disorders
by Zhang, Ao and Neumeyer, John L and Baldessarini, Ross J
Chemical Reviews, ISSN 0009-2665, 01/2007, Volume 107, Issue 1, pp. 274 - 302
IN-VIVO BINDING | BAY X 3702 | PRELIMINARY PHARMACOLOGICAL EVALUATION | POSITRON-EMISSION-TOMOGRAPHY | ASYMMETRIC CONJUGATE ADDITION | ATYPICAL ANTIPSYCHOTIC AGENTS | SEROTONIN REUPTAKE INHIBITION | STRUCTURE-AFFINITY RELATIONSHIPS | CHEMISTRY, MULTIDISCIPLINARY | CHIRAL POOL SYNTHESIS | NONHUMAN PRIMATE BRAIN | Receptors, Dopamine D1 - antagonists & inhibitors | Dopamine Antagonists - chemical synthesis | Dopamine Agonists - chemical synthesis | Humans | Receptors, Dopamine D2 - agonists | Dopamine Agonists - therapeutic use | Nervous System Diseases - drug therapy | Dopamine Antagonists - therapeutic use | Mental Disorders - drug therapy | Receptors, Dopamine D1 - agonists | Molecular Structure | Dopamine Antagonists - chemistry | Dopamine D2 Receptor Antagonists | Dopamine Agonists - chemistry | X-ray crystallography | Research | Stereochemistry | Structure | Observations | Dopamine receptors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Intravenous buspirone for the prevention of postoperative nausea and vomiting
by Kranke, Peter and Röhm, Kerstin D and Diemunsch, Pierre and Gan, Tong J and Apfel, Christian C and Eberhart, Leopold and Minkowitz, Harold S and Wallenborn, Jan and Chassard, Dominique and Lebuffe, Gilles and Fox, Gabriel M and Tramèr, Martin R
European Journal of Clinical Pharmacology, ISSN 0031-6970, 11/2012, Volume 68, Issue 11, pp. 1465 - 1472
Buspirone, a partial 5HT1A agonist and D2 and D3 antagonist, has shown promising antiemetic efficacy when given parenterally in animal models, but its efficacy... 
Biomedicine | Buspirone | Pharmacology/Toxicology | Randomised clinical trial | Antiemetic | Postoperative nausea and vomiting | CATS | MANAGEMENT | 5-HT1A RECEPTORS | ONDANSETRON | AGONISTS | FLESINOXAN | PROPHYLAXIS | ANXIOLYTICS | PHARMACOLOGY & PHARMACY | 5-HT(1A) RECEPTOR | CISPLATIN-INDUCED EMESIS | Anti-Anxiety Agents - administration & dosage | Injections, Intravenous | Buspirone - blood | Dopamine Antagonists - pharmacokinetics | Humans | Middle Aged | Receptors, Dopamine D3 - metabolism | Antiemetics - administration & dosage | Male | Buspirone - pharmacokinetics | Receptors, Dopamine D2 - metabolism | Dopamine Antagonists - administration & dosage | Incidence | Dose-Response Relationship, Drug | Young Adult | Anti-Anxiety Agents - pharmacokinetics | Buspirone - administration & dosage | Antiemetics - pharmacokinetics | Antiemetics - therapeutic use | Aged, 80 and over | Adult | Anti-Anxiety Agents - adverse effects | Antiemetics - adverse effects | Female | Anti-Anxiety Agents - therapeutic use | Buspirone - adverse effects | Receptors, Dopamine D3 - antagonists & inhibitors | Buspirone - therapeutic use | Receptor, Serotonin, 5-HT1A - metabolism | Postoperative Nausea and Vomiting - epidemiology | Double-Blind Method | Dopamine Antagonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - therapeutic use | Serotonin 5-HT1 Receptor Agonists - adverse effects | Postoperative Nausea and Vomiting - prevention & control | Receptor, Serotonin, 5-HT1A - chemistry | Buspirone - analogs & derivatives | Dopamine Antagonists - adverse effects | Serotonin 5-HT1 Receptor Agonists - administration & dosage | Aged | Dopamine D2 Receptor Antagonists | Postoperative Nausea and Vomiting - blood | Prevention | Complications and side effects | Buspirone hydrochloride | Adults | Nausea | Analysis | Postoperative period | Vomiting | Clinical trials | Pharmacology | Drug therapy | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial
by Tariot, Pierre N and Farlow, Martin R and Grossberg, George T and Graham, Stephen M and McDonald, Scott and Gergel, Ivan and for the Memantine Study Group and Memantine Study Grp and Memantine Study Group
JAMA, ISSN 0098-7484, 01/2004, Volume 291, Issue 3, pp. 317 - 324
CONTEXT Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and... 
MEDICINE, GENERAL & INTERNAL | VASCULAR DEMENTIA | INVENTORY | EFFICACY | SEVERE IMPAIRMENT BATTERY | NMDA RECEPTOR ANTAGONIST | INHIBITORS